TIMP-1 Protein Enhances Immune Defense Against Cancer

Researchers at the University of Turku in Finland have found a new function for an existing protein. They discovered that TIMP-1, a protein traditionally known to prevent damage to the body's cells and tissues, plays a critical role in the immune system's defense against cancer. The findings of the study could improve the effectiveness of current cancer immunotherapies.

TIMP-1 protein is produced by dendritic cells, which are responsible for initiating immune responses and boosting the immune system's ability to recognize and destroy cancer cells. The protein enhances antitumor immunity through self-stimulation and by activating surrounding immune cells. As a result, increasing TIMP-1 expression or targeting its negative regulators in tumors with deficient immune responses could potentially improve the effectiveness of current cancer immunotherapies.

For patients deficient in TIMP-1 expression, our discovery helps create rational therapeutic innovations."

Carlos Rogerio Figueiredo, Docent and InFLAMES researcher at the University of Turku

According to Figueiredo, the new findings are also relevant for fighting infections by viruses and bacteria, as the process is part of a universal mechanism that fights microorganisms and cancer in a similar fashion.

The study used samples from the Finnish Auria Biobank for clinical-oriented discoveries, which were further validated with the latest biochemical and immunological tools to propose a new molecular view of how the body fights cancer. Figueiredo thanks the patients as well as Oncologist Maria Sundvall and Pathologist Eva-Maria Birkman from Turku University Hospital for their significant contributions to this project.

"The published research shows how the reverse translational method works in practice. Traditional translational research typically starts with basic laboratory discoveries, which are later tested on patients in clinical trials. The reverse translational approach, on the other hand, starts with real-world data from patient samples to guide focused laboratory studies, thereby enhancing the likelihood of success when applied to patients," explains Figueiredo.

Figueiredo heads the Medical Immuno-Oncology Research Group (MIORG) at the Faculty of Medicine at the University of Turku, which is affiliated with the Turku Bioscience Centre and supported by the Research Council of Finland, InFLAMES Flagship, the Sigrid Juselius Foundation, and the Jane and Aatos Erkko Foundation.

The findings of the study were published in the journal Genes & Immunity, which is part of the Nature Portfolio series.

Source:
Journal reference:

Langguth, M., et al. (2024). TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity. Genes & Immunity. doi.org/10.1038/s41435-024-00274-7.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unveiling IRF1's Influence on Cancer Progression and Treatment